JP6370785B2 - 前立腺がんイメージングのための前立腺特異的抗原薬剤およびその使用方法 - Google Patents
前立腺がんイメージングのための前立腺特異的抗原薬剤およびその使用方法 Download PDFInfo
- Publication number
- JP6370785B2 JP6370785B2 JP2015527444A JP2015527444A JP6370785B2 JP 6370785 B2 JP6370785 B2 JP 6370785B2 JP 2015527444 A JP2015527444 A JP 2015527444A JP 2015527444 A JP2015527444 A JP 2015527444A JP 6370785 B2 JP6370785 B2 JP 6370785B2
- Authority
- JP
- Japan
- Prior art keywords
- agent
- specific antigen
- imaging
- prostate
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261683305P | 2012-08-15 | 2012-08-15 | |
| US61/683,305 | 2012-08-15 | ||
| PCT/US2013/032200 WO2014028057A1 (en) | 2012-08-15 | 2013-03-15 | Prostate specific antigen agents and methods of using same for prostate cancer imaging |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015532641A JP2015532641A (ja) | 2015-11-12 |
| JP2015532641A5 JP2015532641A5 (cg-RX-API-DMAC7.html) | 2016-05-12 |
| JP6370785B2 true JP6370785B2 (ja) | 2018-08-08 |
Family
ID=48170795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015527444A Active JP6370785B2 (ja) | 2012-08-15 | 2013-03-15 | 前立腺がんイメージングのための前立腺特異的抗原薬剤およびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9371362B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2885006B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6370785B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104955484B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013303233C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2882019C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014028057A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2618361T3 (es) | 2005-09-02 | 2017-06-21 | Visen Medical, Inc. | Marcadores colorantes fluorescentes que contienen sulfonamida N,N-disustituida biocompatible |
| US9913917B2 (en) | 2005-12-22 | 2018-03-13 | Visen Medical, Inc. | Biocompatible fluorescent metal oxide nanoparticles |
| AU2009205950C1 (en) | 2008-01-18 | 2015-08-06 | Visen Medical, Inc. | Fluorescent imaging agents |
| JP6122840B2 (ja) | 2011-05-09 | 2017-04-26 | ビセン メディカル， インコーポレイテッド | 炭酸脱水酵素標的化剤およびそれの使用方法 |
| WO2013148319A1 (en) | 2012-03-30 | 2013-10-03 | Visen Medical, Inc. | Bacterial imaging agents and methods of using same |
| AU2013303233C1 (en) | 2012-08-15 | 2018-08-23 | Visen Medical, Inc. | Prostate specific antigen agents and methods of using same for prostate cancer imaging |
| WO2014144702A2 (en) | 2013-03-15 | 2014-09-18 | Visen Medical, Inc. | 4,4-disubstituted cyclohexyl bridged heptamethine cyanine dyes and uses thereof |
| CA2901379C (en) | 2013-03-15 | 2023-05-16 | Visen Medical, Inc. | Substituted silaxanthenium red to near-infrared fluorochromes for in vitro and in vivo imaging and detection |
| US9713649B2 (en) | 2014-01-24 | 2017-07-25 | The Cleveland Clinic Foundation | PSMA-targeting imaging agents |
| ES2992591T3 (en) | 2015-08-18 | 2024-12-16 | Rakuten Medical Inc | Compositions, combinations and related methods for photoimmunotherapy |
| WO2017031363A2 (en) | 2015-08-18 | 2017-02-23 | Aspyrian Therapeutics, Inc. | Methods for manufacturing phthalocyanine dye conjugates and stable conjugates |
| US20200330624A1 (en) * | 2017-10-23 | 2020-10-22 | The Johns Hopkins University | Imaging and radiotherapeutics agents targeting fibroblast-activation protein-alpha (fap-alpha) |
| WO2024181455A1 (ja) * | 2023-02-27 | 2024-09-06 | 富士フイルム株式会社 | 化合物及びこれを用いた標識生体物質 |
| EP4674860A1 (en) * | 2023-02-27 | 2026-01-07 | FUJIFILM Corporation | Compound and labeled biomaterial using same |
| WO2024181456A1 (ja) * | 2023-02-27 | 2024-09-06 | 富士フイルム株式会社 | 化合物及びこれを用いた標識生体物質 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4647447A (en) | 1981-07-24 | 1987-03-03 | Schering Aktiengesellschaft | Diagnostic media |
| US5627027A (en) | 1986-04-18 | 1997-05-06 | Carnegie Mellon University | Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods |
| US5569587A (en) | 1986-04-18 | 1996-10-29 | Carnegie Mellon University | Method for labeling and detecting materials employing luminescent arysulfonate cyanine dyes |
| US5268486A (en) | 1986-04-18 | 1993-12-07 | Carnegie-Mellon Unversity | Method for labeling and detecting materials employing arylsulfonate cyanine dyes |
| US4981977A (en) | 1989-06-09 | 1991-01-01 | Carnegie-Mellon University | Intermediate for and fluorescent cyanine dyes containing carboxylic acid groups |
| DE69332952T2 (de) | 1992-09-04 | 2004-02-19 | The General Hospital Corp., Boston | Diagnostische und therapeutische Einheiten enthaltende biokompatible Polymere |
| US5808044A (en) | 1993-01-22 | 1998-09-15 | Pharmacia Biotech Inc. | Indocarbocyanine and benzindocarbocyanine phosphoramidites |
| US5866679A (en) | 1994-06-28 | 1999-02-02 | Merck & Co., Inc. | Peptides |
| DE4445065A1 (de) | 1994-12-07 | 1996-06-13 | Diagnostikforschung Inst | Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung |
| US6127134A (en) | 1995-04-20 | 2000-10-03 | Carnegie Mellon University | Difference gel electrophoresis using matched multiple dyes |
| US6008373A (en) | 1995-06-07 | 1999-12-28 | Carnegie Mellon University | Fluorescent labeling complexes with large stokes shift formed by coupling together cyanine and other fluorochromes capable of resonance energy transfer |
| IT1276833B1 (it) | 1995-10-09 | 1997-11-03 | Sorin Biomedica Cardio Spa | Coloranti fluorescenti della famiglia della solfo benz e indocianina |
| US6004536A (en) | 1995-11-14 | 1999-12-21 | Molecular Probes, Inc. | Lipophilic cyanine dyes with enchanced aqueous solubilty |
| WO1997040104A1 (en) | 1996-04-19 | 1997-10-30 | Amersham Pharmacia Biotech Uk Limited | Squarate dyes and their use in fluorescent sequencing method |
| US6177404B1 (en) | 1996-10-15 | 2001-01-23 | Merck & Co., Inc. | Conjugates useful in the treatment of benign prostatic hyperplasia |
| DE19717904A1 (de) | 1997-04-23 | 1998-10-29 | Diagnostikforschung Inst | Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie |
| US5877310A (en) | 1997-04-25 | 1999-03-02 | Carnegie Mellon University | Glycoconjugated fluorescent labeling reagents |
| US6127333A (en) | 1997-07-10 | 2000-10-03 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| US6391305B1 (en) | 1997-09-10 | 2002-05-21 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| ZA9810974B (en) | 1997-12-02 | 1999-06-03 | Merck & Co Inc | Conjugates useful in the treatment of prostate cancer |
| PL197006B1 (pl) * | 1997-12-02 | 2008-02-29 | Merck & Co Inc | Koniugat do leczenia raka prostaty, zawierająca go kompozycja farmaceutyczna i jej zastosowanie |
| US6133445A (en) | 1997-12-17 | 2000-10-17 | Carnegie Mellon University | Rigidized trimethine cyanine dyes |
| AU3386399A (en) | 1998-04-08 | 1999-10-25 | Ewald A. Terpetschnig | Luminescent compounds |
| US6002003A (en) | 1998-04-14 | 1999-12-14 | Beckman Instruments, Inc. | Cyanine dye activating group with improved coupling selectivity |
| US6592847B1 (en) | 1998-05-14 | 2003-07-15 | The General Hospital Corporation | Intramolecularly-quenched near infrared flourescent probes |
| US6083486A (en) | 1998-05-14 | 2000-07-04 | The General Hospital Corporation | Intramolecularly-quenched near infrared fluorescent probes |
| US6174858B1 (en) * | 1998-11-17 | 2001-01-16 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| EP1491591B1 (en) | 1999-07-02 | 2009-07-01 | Visen Medical, Inc. | New fluorescence cyanine labels containing a sulfamido linker arm |
| WO2001021624A1 (en) | 1999-09-20 | 2001-03-29 | Fuji Photo Film Co., Ltd. | Compounds for fluorescence labeling |
| AU2002236683A1 (en) | 2000-10-27 | 2002-05-21 | Beth Israel Deaconess Medical Center | Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates |
| US6615063B1 (en) | 2000-11-27 | 2003-09-02 | The General Hospital Corporation | Fluorescence-mediated molecular tomography |
| EP1209205A1 (en) | 2000-11-28 | 2002-05-29 | Innosense S.r.l. | Improved process and method for the preparation of asymetric monofunctionalised indocyanine labelling reagents and obtained compounds |
| EP1221465A1 (en) | 2001-01-03 | 2002-07-10 | Innosense S.r.l. | Symmetric, monofunctionalised polymethine dyes labelling reagents |
| US20030044353A1 (en) | 2001-01-05 | 2003-03-06 | Ralph Weissleder | Activatable imaging probes |
| EP1469989B1 (en) | 2002-01-02 | 2011-12-14 | Visen Medical, Inc. | Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates |
| WO2003061711A2 (en) | 2002-01-16 | 2003-07-31 | Visen Medical, Inc. | Chromophore probes for optical imaging |
| WO2003079015A1 (en) | 2002-03-11 | 2003-09-25 | Visen Medical, Inc. | Optical imaging probes |
| EP2410315B1 (en) | 2002-06-04 | 2020-04-01 | Visen Medical, Inc. | Imaging volumes with arbitrary geometries in contact and non-contact tomography |
| US20060239916A1 (en) | 2005-01-07 | 2006-10-26 | Kai Licha | Use of cyanine dyes for the diagnosis of proliferative diseases |
| TW200624440A (en) | 2005-01-07 | 2006-07-16 | Univ Kaohsiung Medical | Prostate-specific antigen (psa) probes for optical imaging |
| ES2618361T3 (es) | 2005-09-02 | 2017-06-21 | Visen Medical, Inc. | Marcadores colorantes fluorescentes que contienen sulfonamida N,N-disustituida biocompatible |
| US8173819B2 (en) | 2005-09-02 | 2012-05-08 | Visen Medical, Inc. | Nicotinic and picolinic acid derived near-infrared fluorophores |
| DK1937676T3 (en) | 2005-09-02 | 2017-03-06 | Visen Medical Inc | Biocompatible fluorescent imaging compounds |
| US9913917B2 (en) | 2005-12-22 | 2018-03-13 | Visen Medical, Inc. | Biocompatible fluorescent metal oxide nanoparticles |
| US20100189657A1 (en) | 2006-03-20 | 2010-07-29 | The General Hospital Corporation | Intramolecularly quenched fluorochrome conjugates and methods of use |
| WO2008100817A2 (en) | 2007-02-09 | 2008-08-21 | Visen Medical, Inc. | Polycyclo dyes and use thereof |
| WO2008109832A2 (en) | 2007-03-08 | 2008-09-12 | Visen Medical, Inc. | Viable near-infrared fluorochrome labeled cells and methods of making and using same |
| AU2009205950C1 (en) | 2008-01-18 | 2015-08-06 | Visen Medical, Inc. | Fluorescent imaging agents |
| WO2009114776A2 (en) | 2008-03-14 | 2009-09-17 | Visen Medical, Inc. | Integrin targeting agents and methods of using same |
| US8864821B2 (en) | 2008-11-26 | 2014-10-21 | Visen Medical, Inc. | Methods and compositions for identifying subjects at risk of developing stent thrombosis |
| WO2011146143A2 (en) | 2010-05-21 | 2011-11-24 | Ohmx Corporation | Detection of cancer by assaying psa enzymatic activity |
| JP6122840B2 (ja) | 2011-05-09 | 2017-04-26 | ビセン メディカル， インコーポレイテッド | 炭酸脱水酵素標的化剤およびそれの使用方法 |
| AU2013303233C1 (en) | 2012-08-15 | 2018-08-23 | Visen Medical, Inc. | Prostate specific antigen agents and methods of using same for prostate cancer imaging |
-
2013
- 2013-03-15 AU AU2013303233A patent/AU2013303233C1/en active Active
- 2013-03-15 US US13/839,413 patent/US9371362B2/en active Active
- 2013-03-15 CN CN201380053922.2A patent/CN104955484B/zh active Active
- 2013-03-15 CA CA2882019A patent/CA2882019C/en active Active
- 2013-03-15 EP EP13718240.8A patent/EP2885006B1/en active Active
- 2013-03-15 JP JP2015527444A patent/JP6370785B2/ja active Active
- 2013-03-15 WO PCT/US2013/032200 patent/WO2014028057A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20140050662A1 (en) | 2014-02-20 |
| JP2015532641A (ja) | 2015-11-12 |
| WO2014028057A1 (en) | 2014-02-20 |
| CN104955484A (zh) | 2015-09-30 |
| EP2885006B1 (en) | 2018-08-08 |
| US9371362B2 (en) | 2016-06-21 |
| CA2882019A1 (en) | 2014-02-20 |
| AU2013303233A1 (en) | 2015-03-05 |
| CA2882019C (en) | 2021-02-09 |
| AU2013303233C1 (en) | 2018-08-23 |
| CN104955484B (zh) | 2019-01-15 |
| AU2013303233B2 (en) | 2018-05-17 |
| EP2885006A1 (en) | 2015-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6370785B2 (ja) | 前立腺がんイメージングのための前立腺特異的抗原薬剤およびその使用方法 | |
| US12110283B2 (en) | Carbonic anhydrase targeting agents and methods of using same | |
| US9375493B2 (en) | Bacterial imaging agents and methods of using same | |
| JP5586485B2 (ja) | インテグリン標的化剤およびそれらを用いるｉｎｖｉｖｏおよびｉｎｖｉｔｒｏでの画像化方法 | |
| US8815214B2 (en) | Fluorescent imaging agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160314 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160314 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161129 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170208 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170526 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171018 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180111 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180315 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180412 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180613 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180711 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6370785 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |